Benjamín Morales TrejoLuis Carbajal Bello
Atherosclerosis (AS) is a leading cause of the life-threatening cardiovascular disease (CVD), creating an urgent need for efficient, biocompatible therapeutics for diagnosis and treatment. Biomimetic nanomedicines (bNMs) are moving closer to fulfilling this need, pushing back the frontier of nano-based drug delivery systems design. This review seeks to outline how these nanomedicines (NMs) might work to diagnose and treat atherosclerosis, to trace the trajectory of their development to date and in the coming years, and to provide a foundation for further discussion about atherosclerotic theranostics.
Carlos Alberto Carrasco RuedaIlan Vinitzky BrenerPedro Nicolás BautistaBeatríz Catalina Aldape Barrios
Josué Caicedo SalazarLeonardo Germánico Orellana NarváezDaniel Delgado-PiedraJuan Marcos Parise-Vasco
Dailyn Rodríguez RodríguezCarlos Eduardo Valera IbáñezDaniel Medécigo CosteiraJosé Ernesto Miranda VillasanaJosé Eduardo Cruz López
Roque Oscar RosendeCarlos RosalesPatricia ZarzaSebastián Krupp
Raúl Narváez RuizTania Chávez PriegoRoberto Onner Cruz TapiaErnesto Manrique IslasAdriana Lizeth Jerónimo Hernández